Lidocaine vaginal - Enhance Pharmaceuticals
Latest Information Update: 24 Apr 2007
At a glance
- Originator Enhance Pharmaceuticals
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
- Mechanism of Action Cell membrane permeability inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaesthesia
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Anaesthesia in USA (Vaginal)
- 17 Jun 2002 Enhance Pharmaceuticals has been acquired by Barr Laboratories
- 28 Mar 2002 Barr Laboratories expects to acquire Enhance, subject to conditions, by June 30, 2002